DX
Disease-Modifying Therapy

Thursday, May 31, 2018: 6:30 PM-7:30 PM
Exhibit Hall A (Nashville Music City Center)
Selective S1PR1/S1PR5 Modulation Impacts Neurologic Architecture/Function By Improving Kinematic Gait and Protecting from Neuronal Breaks in a Demyelinating Mouse Model
Kristen R. Taylor Meadows, PhD, Receptos, a wholly owned subsidiary of Celgene; Kevin C. Dines, PhD, Receptos, a wholly owned subsidiary of Celgene; Gregory J. Opiteck, PhD, Receptos, a wholly owned subsidiary of Celgene; Fiona L. Scott, PhD, Receptos, a wholly owned subsidiary of Celgene
PDF
PDF
Analysis of Lymphocyte Counts and Infection Rates with Fingolimod in Patients with Primary Progressive Multiple Sclerosis over the Informs Trial
Edward J. Fox, MD, PhD, Central Texas Neurology Consultants; Fred Lublin, MD, Icahn School of Medicine at Mount Sinai; Jerry S Wolinsky, MD, McGovern Medical School, UTHealth; Jeffrey A Cohen, MD, Cleveland Clinic Foundation; Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation; Marina Ziehn, PhD, Novartis Pharmaceuticals Corporation; Scott Kolodny, MD, Novartis Pharmaceuticals Corporation; Norman Putzki, MD, Novartis Pharmaceuticals Corporation; Bruce AC Cree, MD, PhD, Weill Institute for Neurosciences
PDF
Efficacy of a Fourth Alemtuzumab Course in RRMS Patients with Disease Activity after Three Prior Courses: Analysis of Care-MS II
Barry A Singer, MD, MS Center for Innovations in Care, Missouri Baptist Medical Center; Raed Alroughani, MD, Amiri Hospital; Aaron Boster, MD, OhioHealth Neurological Physicians; Ann D. Bass, MD, Neurology Center of San Antonio; Regina Berkovich, MD, PhD, University of Southern California, Keck School of Medicine; Giancarlo Comi, MD, University Vita-Salute San Raffaele; Oscar Fernandez, MD, Fundacion IMABIS, Hospital Universitario Carlos Haya; Ho Jin Kim, MD, Research Institute and Hospital of National Cancer Center; Volker Limmroth, MD, PhD, Klinik fur Neurologie und Palliativmedizin; Jan Lycke, MD, Sahlgrenska University Hospital; Richard AL Macdonell, MD, Austin Health and Florey Institute of Neuroscience and Mental Health; Basil Sharrack, MD, PhD, Sheffield Teaching Hospitals NHS Foundation Trust; Patrick Vermersch, MD, University of Lille; Heinz Wiendl, MD, University of Munster; Tjalf Ziemssen, MD, PhD, Carl Gustav Carus University Hospital; Maria Melanson, MD, PhD, Sanofi; Nadia Daizadeh, PhD, Sanofi; Anthony Traboulsee, MD, University of British Columbia; on behalf of the CARE-MS II and CAMMS03409, Investigators, on behalf of the CARE-MS II and CAMMS03409 Investigators
PDF
Durable Clinical Improvements with Alemtuzumab in RRMS Patients in the Absence of Continuous Treatment: 7-Year Follow-up of Care-MS II (TOPAZ Study)
Barry A Singer, MD, MS Center for Innovations in Care, Missouri Baptist Medical Center; Raed Alroughani, MD, Amiri Hospital; Simon Broadley, MD, School of Medicine, Gold Coast Campus, Griffith University; Hans-Peter Hartung, MD, Heinrich-Heine University; Eva Kubala Havrdova, MD, PhD, First Medical Faculty, Charles University in Prague; Ho Jin Kim, MD, Research Institute and Hospital of National Cancer Center; Celia Oreja-Guevara, MD, University Hospital San Carlos; Carlo Pozzilli, MD, Sapienza University of Rome; Patrick Vermersch, MD, University of Lille; Sibyl Wray, MD, Hope Neurology MS Center; Luke Chung, MD, MPH, Sanofi; Nadia Daizadeh, PhD, Sanofi; Madalina Chirieac, MD, MPH, Sanofi; Krzysztof W Selmaj, MD, Medical University of Lodz; on behalf of the CARE-MS II, CAMMS03409, and TOPAZ, Investigators, on behalf of the CARE-MS II, CAMMS03409, and TOPAZ Investigators
PDF
Real-World Disease Burden and Treatment Experiences of Patients with MS in the US: Results from the Vsms Survey
Ann D. Bass, MD, Neurology Center of San Antonio; Bart Van Wijmeersch, MD, PhD, Rehabilitation & MS-Centre Overpelt, BIOMED, Hasselt University; Aaron Boster, MD, OhioHealth Neurological Physicians; Lori Mayer, DNP, MSN, RN, MSCN, Central Texas Neurology Consultants; Mathias Maurer, MD, Klinikum Wurzburg Mitte gGmbH; Matt Mandel, MD, Sanofi; Kersten Sharrock, MS, Sanofi; Colin P Mitchell, PhD, Sanofi; Barry A Singer, MD, MS Center for Innovations in Care, Missouri Baptist Medical Center
PDF
A Single-Center Review Of Therapies Used Prior To Alemtuzumab In Patients With Multiple Sclerosis
Suma Shah, MD, Duke University; Anastasie Dunn-Pirio, MD, MS, Duke University; Jenelle M. Hall, PharmD, Duke University Health System; Bryan Walker, PA-C, Duke University; Nick Hudak, PA-C, Duke University; Fletcher Hartsell, MD, Duke University; Mark Skeen, MD, Duke University; Christopher Eckstein, MD, Duke University
PDF
Effects of Cladribine Tablets on MRI Outcomes in High Disease Activity (HDA) Patients with Relapsing Multiple Sclerosis (RMS) in the Clarity Study
Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath, Queen Mary University London, Blizard Institute, Barts and the London School of Medicine and Dentistry; Kottil Rammohan, MD, Ohio State University Hospital; Stuart Cook, MD, Rutgers, The State University of New Jersey, New Jersey Medical School; Giancarlo Comi, MD, Vita-Salute San Raffaele University; Peter Rieckmann, MD, Akademisches Krankenhaus Sozialstiftung Bamberg; Per Soelberg Soerensen, MD, University of Copenhagen; Patrick Vermersch, MD, University of Lille; Fernando Dangond, MD, EMD Serono, Inc.; Christine Hicking, MS, Merck KGaA
PDF
A Post Hoc Analysis of No Evidence of Disease Activity (NEDA) in Patients with Highly Active RMS Who Were Treated with Cladribine Tablets in Clarity
Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath, Queen Mary University London, Blizard Institute, Barts and the London School of Medicine and Dentistry; Kottil Rammohan, MD, Ohio State University Hospital; Stuart Cook, MD, Rutgers, The State University of New Jersey, New Jersey Medical School; Giancarlo Comi, MD, Vita-Salute San Raffaele University; Peter Rieckmann, MD, Akademisches Krankenhaus Sozialstiftung Bamberg; Per Soelberg Soerensen, MD, University of Copenhagen; Patrick Vermersch, MD, University of Lille; Fernando Dangond, MD, EMD Serono, Inc.; Christine Hicking, MS, Merck KGaA
PDF
Number-Needed-to-Treat Analyses Comparing Clinical Disease Outcomes and Disability Improvement in RMS Patients Treated with Alemtuzumab or Ocrelizumab
Aaron Boster, MD, OhioHealth Neurological Physicians; Bart Van Wijmeersch, MD, PhD, Rehabilitation & MS-Centre Overpelt, BIOMED, Hasselt University; Raed Alroughani, MD, Amiri Hospital; Giancarlo Comi, MD, University Vita-Salute San Raffaele; Regina Berkovich, MD, PhD, University of Southern California, Keck School of Medicine; Guillermo Izquierdo, MD, Virgen Macarena University Hospital; Daniel Kantor, MD, Florida Atlantic University; Christopher LaGanke, MD, North Central Neurology Associates; Volker Limmroth, MD, PhD, Klinik fur Neurologie und Palliativmedizin; Richard AL Macdonell, MD, Austin Health and Florey Institute of Neuroscience and Mental Health; Heinz Wiendl, MD, University of Munster; Maria Melanson, MD, PhD, Sanofi; Karthinathan Thangavelu, PhD, Sanofi; Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute; on behalf of the CAMMS223, CARE-MS I, and CARE-MS II, Investigators, on behalf of the CAMMS223, CARE-MS I, and CARE-MS II Investigators
PDF
Alemtuzumab Use Among Narcoms Registry Participants
Amber Salter, PhD, Washington University in St Louis; Tuula Tyry, PhD, Dignity Health, St. Joseph's Hospital and Medical Center; Robert J Fox, MD, Cleveland Clinic; Ruth Ann Marrie, MD, PhD, University of Manitoba; Lobat Hashemi, ScD, Sanofi; Kathryn Munoz, MPH, PhD, Sanofi; Thomas Carattini, PharmD, Sanofi; Alden Smith, PharmD, Sanofi; Gary Cutter, PhD, University of Alabama at Birmingham
PDF
Teriflunomide Use in Participants with Relapsing-Remitting MS Enrolled in the Narcoms Registry
Amber Salter, PhD, Washington University in St Louis; Tuula Tyry, PhD, Dignity Health, St. Joseph's Hospital and Medical Center; Samantha Lancia, MS, Washington University in St Louis; Robert J Fox, MD, Cleveland Clinic; Ruth Ann Marrie, MD, PhD, University of Manitoba; Lobat Hashemi, ScD, Sanofi; Kathryn Munoz, MPH, PhD, Sanofi; Thomas Carattini, PharmD, MBA, Sanofi; Alden Smith, PharmD, Sanofi; Gary Cutter, PhD, University of Alabama at Birmingham

Treatment Retention and Satisfaction in Patients Randomized to Fingolimod or Injectable Disease-Modifying Therapies in PREFERMS: Effect of Previous Treatment
Florian P Thomas, MD, PhD, MA, Seton Hall-Hackensack Meridian School of Medicine; Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute; Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation; Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation; Scott Kolodny, MD, Novartis Pharmaceuticals Corporation; Nadia Tenenbaum, MD, Novartis Pharmaceuticals Corporation; Bruce AC Cree, MD, PhD, Weill Institute for Neurosciences
PDF
Early Impact of Expanding Generic Glatiramer Acetate Options Confined to Payer-Driven Conversion/Competition within Glatiramer Acetate Class
Virginia R Schobel, MSc, Spherix Global Insights; Jennifer Robinson, BS, Spherix Global Insights
PDF
Early Uptake Analysis of Ocrelizumab Highlights Shifting and Distinct Treatment Paradigms By Multiple Sclerosis Subtypes
Virginia R Schobel, MSc, Spherix Global Insights; Jennifer Robinson, BS, Spherix Global Insights
PDF
PDF
Long-Term Predictors of Clinical Outcomes in Patients with Multiple Sclerosis in the Phase 3 Freedoms, Freedoms II and Transforms Studies
Till Sprenger, MD, DKD HELIOS Klinik; Aaron Boster, MD, OhioHealth Neurological Physicians; Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation; Shannon Ritter, MS, Novartis Pharmaceuticals Corporation; Daniela Piani Meier, PhD, Novartis Pharma AG; Davorka Tomic, PhD, Novartis Pharma AG; Diego Silva, MD, PhD, Novartis Pharma AG; Frederik Barkhof, MD, PhD, Institutes of Neurology and Healthcare Engineering, University College London; Pavle Repovic, MD, PhD, Multiple Sclerosis Center, Swedish Neuroscience Institute
PDF
Current Correlations between Disease Modifiers & Physiologic Measurements from the MS Mosaic Study
Fletcher L Hartsell III, MD MPH, Duke University School of Medicine
PDF
Acapella: Real World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS
Kelly F Luciani, B.S., The Elliot Lewis Center for Multiple Sclerosis Care; Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care; Ellen S Lathi, M.D., The Elliot Lewis Center for Multiple Sclerosis Care; Hannah M Geils, B.S., The Elliot Lewis Center for Multiple Sclerosis Care
PDF
The Importance of the Role of a Patient Safety Coordinator in a Comprehensive Multiple Sclerosis Center.
Vineet Nadkarni, BS, University of Florida; Tirisham V Gyang, MD, University of Florida; Lindsay Falk, ARNP, University of Florida; Augusto Miravalle, MD, University of Florida

Evaluation of Multiple Sclerosis Patients' Disease Modifying Therapy Prior to and after Disease Relapse
Sharon R Tingen, PharmD, BCPS, University of Virginia; Myla D Goldman, MD, Msc, University of Virginia; Robert D'Eramo, PharmD, University of Virginia
PDF
A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms from Pegylated Interferon Beta-1a
Anthony M Iuso, BS, Holy Name Medical Center; Mary Ann Picone, MD, Holy Name Medical Center; Karen Blitz, DO, South Shore Neurologic Associates
PDF
Effect of Montelukast on GI Tolerability in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Delayed-Release Dimethyl Fumarate: Mitigate Study Results
Carlo Tornatore, MD, Medstar Georgetown University Hospital; Teri Schreiner, MD MPH, Children's Hospital Colorado; Kyle E Smoot, MD, Providence Multiple Sclerosis Center; Natasha Frost, M.D., School of Medicine and Public Health, University of Wisconsin; Oksana Mokliatchouk, PhD, Biogen; Christophe Hotermans, MD, Biogen; Irene Koulinska, MD, ScD, Biogen
PDF
Pregnancy Outcomes with Ozanimod: Data from the Clinical Development Program
Denise Campagnolo, MD, Celgene Corporation; Catherine Montero-Embalsado, BS, Receptos, a wholly owned subsidiary of Celgene; Susan Meier-Davis, DVM, PhD, DABT, Receptos, a wholly owned subsidiary of Celgene; Neil Minton, MD, Receptos, a wholly owned subsidiary of Celgene

Patients' Preferences and Willingness-to-Pay for Disease-Modifying Therapies: A Discrete Choice Experiment in the U.S.
Surachat Ngorsuraches, Ph.D., College of Pharmacy and Allied Health Professions, South Dakota State University; Natasha Frost, M.D., School of Medicine and Public Health, University of Wisconsin; Jerome Freeman, M.D., F.A.C.P., Sanford School of Medicine, University of South Dakota; Diana Brixner, R.Ph., Ph.D., FAMCP, College of Pharmacy, University of Utah; Jane Mort, Pharm.D., College of Pharmacy and Allied Health Professions, South Dakota State University; James Clem, Pharm.D., College of Pharmacy and Allied Health Professions, South Dakota State University
PDF
Pain in Multiple Sclerosis, Is Dimethyl Fumarate Associated to Less Pain, When Compared to Other Disease Modifying Therapies?
Amputch Karukote, MD, Texas Tech University Health Sciences Center; Volker Neugebauer, MD, PHD, Texas Tech University Health Sciences Center; Mirla Avila, MD, Texas Tech University Health Sciences Center
PDF
Simultaneous Use of Immunoglobulin with Natalizumab Attenuates the JCV Stratify Index Elevation- a 2 Year Analysis
Ronald Bailey, M.D., The Neurology Group; Marco Pasco, MPH, The Neurology Group; Taif Kaissi, M.D., The Neurology Group; Shard Yaqoot, R.N., CA Specialty Pharmacy; Bhavesh Desai, D. Pharm, J.D., CA Specialty Pharmacy; Maria Aziz, A.S., The Neurology Group
PDF
Stevens-Johnson Syndrome Associated with Daclizumab Use- Report of Two Cases
Ronald Bailey, M.D., The Neurology Group; Marco Pasco, MPH, The Neurology Group; Shard Yaqoot, R.N., CA Specialty Pharmacy
PDF
Beltrims: Belgian Treatment Registry in MS
Barbara Willekens, MD, Antwerp University Hospital; Vincent Van Pesch, MD, PhD, Cliniques Universitaires Saint-Luc; Souraya El Sankari, MD, PhD, Cliniques Universitaires St-Luc; Benedicte Dubois, PhD/MD, KU Leuven; Marie D'Hooghe, MD, PhD, National MS Center; Guy Nagels, MD, PhD, National Multiple Sclerosis Center; Daniel Guillaume, MD, PhD, Centre neurologique et de readaption fonctionelle de Fraiture-en-Condroz; Pierrette Seeldrayers, MD, PhD, Centre Hospitalier Universitaire Charleroi; On behalf of the Belgian Study Group for Multiple Sclerosis, -, BSGMS

Patient Perspectives on Factors Related to Medication Persistence in MS Patients Experiencing DMF-Associated Gastrointestinal Events
Barry Hendin, M.D., Phoenix Neurological Associates; Lori Mayer, DNP, MSN, RN, MSCN, Central Texas Neurology Consultants; Marie Namey, APRN, MSCN, Cleveland Clinic; Michael R Edwards, PhD, Biogen; Beth Jordan, MBA, Biogen; Leslie Beth Herbert, PhD, Health Union, LLC; Irene Koulinska, MD, ScD, Biogen
PDF
Long-Term Follow up of Treatment with Interferon Beta 1-b in a Cohort of 87 Patients with Multiple Sclerosis: A 23-Year Observational Study in a Single Center
Mirela Cerghet, MD, PhD, Henry Ford Hospital; Ahmad M Siddiqi, MD, Henry Ford Health System; Lonni Schultz, PhD, Henry Ford Health System; Helena Bulka, DO, Henry Ford Hospital; Carol Freeman, BSci, NP, Henry Ford Health System; Stanton Elias, MD, Henry Ford Hospital
PDF
Transition from Natalizumab to Dimethyl Fumarate in Multiple Sclerosis Patients: Clinical and MRI Outcomes
Mark Waheed, DO, University of Utah School of Medicine; John W Rose, MD, University of Utah School of Medicine; Ka-ho Wong, BS, University of Utah School of Medicine; Stacey Clardy, MD PhD, University of Utah School of Medicine; Julia Klein, APRN, University of Utah School of Medicine; M. Mateo Paz Soldan, MD PhD, University of Utah School of Medicine; Lucy D Dewitt, MD, University of Utah School of Medicine; John Steffens, MD, University of Utah School of Medicine
PDF
Moderate-to-Vigorous Physical Activity Is Positively Associated with the Retinal Nerve Fibre Layer Thickness in Pediatric Multiple Sclerosis
Alexander L Pearson, BA, University of Ottawa; Stephanie A Grover, MSc, CCRP, The Hospital for Sick Children; Danusha Nandamalavan, BSc, CCRA, The Hospital for Sick Children; Tara Berenbaum, BSc, The Hospital for Sick Children; Robert W Motl, PhD, University of Alabama at Birmingham; Marcia Finlayson, PhD, OT Reg (Ont), OTR, Queen's University; Brenda Banwell, MD, Children's Hospital of Philadelphia; E. Ann Yeh, MD, MA, FRCPC, Dip ABPN, The Hospital for Sick Children
PDF
Life-Threatening Tumefactive Rebound of Multiple Sclerosis Following Fingolimod Discontinuation
Mihir Kakara, M.D., Wayne State University School of Medicine; Jay Kinariwala, M.D., Wayne State University School of Medicine; Shitiz K Sriwastava, M.D., Wayne State University School of Medicine; Evanthia Bernitsas, MD, Wayne State University School of Medicine
PDF
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis
Stephen L Hauser, MD, University of California, San Francisco; Ludwig Kappos, MD, University of Basel; Xavier Montalban, MD, PhD, Vall díHebron University Hospital; Harold Koendgen, MD PhD, F. Hoffmann-La Roche Ltd; Carrie Li, PhD, F. Hoffmann-La Roche Ltd; Carole Marcillat, Pharm. D, F. Hoffmann-La Roche Ltd; Ashish Pradhan, MD, Genentech, Inc.; David Wormser, MSc, MPhil PhD, F. Hoffmann-La Roche Ltd; Jerry S Wolinsky, MD, UTHealth
PDF
An Update on Pregnancy Outcomes Following Ocrelizumab Treatment in Patients with Multiple Sclerosis and Other Autoimmune Diseases
Sibyl Wray, MD, Sibyl Wray MD Neurology PC; Ludwig Kappos, MD, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel; Sandra Vukusic, MD, PhD, Hopital Neurologique Pierre Wertheimer; Silvia Bader-Weder, MD, F. Hoffmann-La Roche Ltd; Regine Buffels, MD, F. Hoffmann-La Roche Ltd; Donna Masterman, MD, MS, Genentech Inc.; Julie Napieralski, PhD, F. Hoffmann-La Roche Ltd; Stephen L Hauser, MD, University of California, San Francisco
PDF
Routine Laboratory Measures in the Controlled Treatment Period of Phase III Ocrelizumab Trials in Relapsing and Progressive Multiple Sclerosis
Jerry S Wolinsky, MD, McGovern Medical School, UTHealth; Ludwig Kappos, MD, University of Basel; Xavier Montalban, MD, PhD, Vall díHebron University Hospital; Cathy Chognot, PhD, F. Hoffmann-La Roche Ltd; Harold Koendgen, MD PhD, F. Hoffmann-La Roche Ltd; Carrie Li, PhD, F. Hoffmann-La Roche Ltd; Ashish Pradhan, MD, Genentech, Inc.; Stephen L Hauser, MD, University of California, San Francisco
PDF
Prespecified Subgroup Analyses of Ocrelizumab Efficacy in Patients with Primary Progressive Multiple Sclerosis from the Phase III Oratorio Study
Jerry S Wolinsky, MD, McGovern Medical School, UTHealth; Xavier Montalban, MD, PhD, Division of Neurology, University of Toronto; Stephen L Hauser, MD, University of California, San Francisco; Ludwig Kappos, MD, University Hospital Basel, University of Basel; Laura Julian, PhD, Genentech, Inc.; Marianna Manfrini, MD PhD, F. Hoffmann-La Roche Ltd; Shibeshih Belachew, MD, PhD, F. Hoffmann-La Roche Ltd; Fabian Model, PhD, F. Hoffmann-La Roche Ltd; Stanislas Hubeaux, MSc, F. Hoffmann-La Roche Ltd; Amit Bar-Or, MD, University of Pennsylvania
PDF
Effect of Ocrelizumab on Vaccine Responses in Patients with Multiple Sclerosis
Daniela Stokmaier, MSc Pharm PhD, F.Hoffmann-La Roche Ltd; Kevin Winthrop, MD MPH, OHSU; Cathy Chognot, PhD, F. Hoffmann-La Roche Ltd; Joanna Evershed, BSc, Roche Products Ltd; Marianna Manfrini, MD PhD, F. Hoffmann-La Roche Ltd; John McNamara, BSc MSc CStat, John McNamara Consulting Limited; Amit Bar-Or, MD, University of Pennsylvania
PDF
Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Postmarketing Data
Patricia K Coyle, MD, Stony Brook University; Sandra Vukusic, MD, PhD, University Hospital of Lyon; Stephanie Jurgensen, MPH, Sanofi; Philippe Truffinet, MD, Sanofi; Myriam Benamor, MD, Sanofi; Elizabeth Poole, PhD, Sanofi; Jeffrey Chavin, MD, Sanofi; Christina Chambers, PhD, University of California San Diego

Brain MRI Activity and Atrophy in Ocrelizumab-Treated Relapsing Multiple Sclerosis Patients in the Open-Label Extension of the Pooled Opera Trials
Anthony Traboulsee, MD, The University of British Columbia; Douglas L Arnold, MD, NeuroRx Research; Ludwig Kappos, MD, University of Basel; Stephen L Hauser, MD, University of California; Xavier Montalban, MD, PhD, Vall díHebron University Hospital; Jerry S Wolinsky, MD, McGovern Medical School, UTHealth; Victoria Levesque, PhD, Genentech, Inc.; Pablo Villoslada, MD, Genentech, Inc.; Shibeshih Belachew, MD, PhD, F. Hoffmann-La Roche Ltd; Fabian Model, PhD, F. Hoffmann-La Roche Ltd; Stanislas Hubeaux, MSc, F. Hoffmann-La Roche Ltd; Amit Bar-Or, MD, University of Pennsylvania
PDF
Infusion-Related Reactions with Ocrelizumab in the Phase III Studies
Jerome de Seze, MD PhD, University Hospital of Strasbourg; Stephen L Hauser, MD, University of California, San Francisco; Ludwig Kappos, MD, University of Basel; Xavier Montalban, MD, PhD, Vall díHebron University Hospital; Carlo Pozzilli, MD, Sapienza University of Rome; Cathy Chognot, PhD, F. Hoffmann-La Roche Ltd; Laura Julian, PhD, Genentech, Inc.; Harold Koendgen, MD PhD, F. Hoffmann-La Roche Ltd; Hanzhe Zheng, PhD, Genentech, Inc.; Jerry S Wolinsky, MD, McGovern Medical School, UTHealth
PDF
Effect of Long-Term Teriflunomide Treatment on Lymphocyte Counts and Infection Rates in Pooled Data from Temso, Tower, and TOPIC Core and Extension Studies
Aaron E Miller, MD, Icahn School of Medicine at Mount Sinai; Giancarlo Comi, MD, University Vita-Salute San Raffaele; Myriam Benamor, MD, Sanofi; Philippe Truffinet, MD, Sanofi; Karthinathan Thangavelu, PhD, Sanofi; Jeffrey Chavin, MD, Sanofi; Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute

Effect of Teriflunomide on Substantial Disability Worsening in Patients with Relapsing Forms of MS in the Phase 3 Tower Study
Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute; Aaron E Miller, MD, Icahn School of Medicine at Mount Sinai; Elizabeth Poole, PhD, Sanofi; Jeffrey Chavin, MD, Sanofi; Philippe Truffinet, MD, Sanofi; Ludwig Kappos, MD, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel

Ocrelizumab Pregnancy Registry to Assess Maternal, Fetal and Infant Outcomes in Women with Multiple Sclerosis Exposed to Ocrelizumab during Pregnancy
David Wormser, MSc, MPhil PhD, F. Hoffmann-La Roche Ltd; Pierre Engel, PharmD, MPH, PhD, QuintilesIMS; Kristen Hahn, MPH, PhD, QuintilesIMS; Silvia Bader-Weder, MD, F. Hoffmann-La Roche Ltd; Eva-Maria Didden, PhD, F. Hoffmann-La Roche Ltd; Joanna Evershed, BSc, Roche Products Ltd; Monika Garas, PhD, F. Hoffmann-La Roche Ltd; Qing Wang, PhD, F. Hoffmann-La Roche Ltd; Kerstin Hellwig, PhD MD, Ruhr University; Ashish Pradhan, MD, Novartis Pharmaceuticals Corporation
PDF
Post-Marketing Study to Evaluate Pregnancy and Infant Outcomes in Women with Multiple Sclerosis Exposed to Ocrelizumab during Pregnancy
Andrea V Margulis, MD ScD, RTI Health Solutions; Elizabeth B Andrews, PhD MPH, RTI Health Solutions; Sonia Hernandez-Diaz, MD DrPH, Harvard University; Melinda Magyari, MD PhD, Copenhagen University Hospital; Elena Rivero-Ferrer, MD MPH, RTI Health Solutions; Silvia Bader-Weder, MD, F. Hoffmann-La Roche Ltd; Joanna Evershed, BSc, Roche Products Ltd; Monika Garas, PhD, F. Hoffmann-La Roche Ltd; Qing Wang, PhD, F. Hoffmann-La Roche Ltd; David Wormser, MSc, MPhil PhD, F. Hoffmann-La Roche Ltd; Ashish Pradhan, MD, Novartis Pharmaceuticals Corporation
PDF
Efficacy Outcomes in Patients Randomized to Fingolimod or Injectable Disease-Modifying Therapies in PREFERMS: Effect of Previous Treatment Cycles
Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute; Florian P Thomas, MD, PhD, MA, Seton Hall-Hackensack Meridian School of Medicine; Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation; Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation; Scott Kolodny, MD, Novartis Pharmaceuticals Corporation; Nadia Tenenbaum, MD, Novartis Pharmaceuticals Corporation; Bruce AC Cree, MD, PhD, Weill Institute for Neurosciences
PDF
Changes in Whole Brain Volume and Cortical Gray Matter over 2 Years of Natalizumab Treatment: Results from the Strive Study
Jai Perumal, MD, Judith Jaffe Multiple Sclerosis Center; Robert J Fox, MD, Cleveland Clinic; Roumen Balabanov, MD, Northwestern University; Laura J Balcer, MD, MSCE, New York University Langone Medical Center; Steven Galetta, MD, New York University Langone Medical Center; Shavy Makh, MPhil, Biogen; Sourav Santra, PhD, Biogen; Elizabeth Fisher, PhD, Biogen; Christophe Hotermans, MD, PhD, Biogen; Lily Lee, MD, Biogen
PDF
Review of Immunization Status of Patients Switched to Ocrelizumab: A Tertiary Care Experience
Lakshman Arcot Jayagopal, MD, University of Washington; Deb Cramer, RN, BSN, MSCN, University of Washington; Wendy Durand, RN BSN, University of Washington; Deborah Gallaro, RPH, University of Washington; Bren Hammond, RN, BSN, MSCN, University of Washington; Michael Persenaire, MD, University of Washington; Gary Stobbe, MD, University of Washington; Jennie Toro, RN, University of Washington; Gloria von Geldern, MD, University of Washington; Annette Wundes, MD, University of Washington
PDF
Real-World Characterization of Flu-like Symptom Severity and Duration in Patients with RMS: Interim Analysis of the Peginterferon Beta-1a Pop Study
Maria L Naylor, PhD, Biogen; Marco Salvetti, MD, Sant' Andrea Hospital; Jang Yun, MS, PhD, Biogen; Craig Wakeford, MA, Biogen; Sibyl Wray, MD, Hope Neurology MS Center
PDF
The Importance of Pharmacist Involvement in Laboratory Adherence for Patients on Disease Modifying Therapy for Multiple Sclerosis, Utilizing a Clinical Dashboard
Dante M Grassi, Pharm D., BCPS, Geisinger; Amanda Sharry-Rogers, Pharm D., BCPS, Geisinger; Ashley L Lauver, Pharm D., Geisinger; Douglas C Nathanson, MD, Geisinger; Joseph J Chronowski, MBA, BA, Geisinger; Jove Graham, PhD, Geisinger
PDF
Potential Infectious Complications of B-Cell Depleting Therapies-a Focus on Rituximab in Multiple Sclerosis
Cindy Darius, MS, RN, Johns Hopkins School of Medicine; Maureen A. Mealy, PhD(c), RN, Johns Hopkins University School of Nursing; Megan Esch, MD, The Johns Hopkins School of Medicine; Salman Aljarallah, MBBS FRCPC, Johns Hopkins School of Medicine; Kathleen Costello, MS, ANP-BC, MSCN, National Multiple Sclerosis Society; Lisa Fox, PA-C MPAS, Johns Hopkins School of Medicine; Shiv Saidha, MBBCh, Johns Hopkins University

Baseline Cognitive Function of Patients with Relapsing Remitting Multiple Sclerosis Is Associated with Therapeutic Response to Natalizumab
Daniel Golan, MD, Technion-Israel Institute of Technology; Mark Gudesblatt, MD, South Shore Neurologic Associates; Karl Wisseman, N/A, South Shore Neurologic Associates; Myassar Zarif, MD, South Shore Neurologic Associates; Barbara Bumstead, MS, ANCP, MSCN, South Shore Neurologic Associates; Lori Fafard, RN, BSN, CNRN, MSCN, CCRP, South Shore Neurologic Associates; Cynthia Sullivan, PhD, State University of New York @ Stony Brook; Jeffrey Wilken, PhD, Washington Neuropsychology Research Group; Jared Srinivasan, N/A, South Shore Neurologic Associates; Karen Blitz, DO, South Shore Neurologic Associates; Marijean Buhse, PhD, NP, RN, MSCN, Stony Brook University; Glen Doniger, PhD, NeuroTrax Corporation

Characterization of the Hispanic MS Patient on Alemtuzumab
Angel Chinea, MD, San Juan Multiple Sclerosis Center; Ivonne Vicente, MD, San Juan Multiple Sclerosis Center; Cristina M Rubi, BS, San Juan Multiple Sclerosis Center; Allan J Reyes, BA, San Juan MS Center; Astrid Diaz, BS, San Juan MS Center; Genesis Burgos, HS, San Juan MS Center

Leflunomide for the Treatment of Multiple Sclerosis: A Case Series
Daniel Kantor, MD, Florida Atlantic University; Asya I. Wallach, MD, NYU School of Medicine; Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute; Christopher W. Milligan, MS, PA-C, Advanced Neurosciences Institute; Ajay S Gupta, MD, Fort Wayne Neurological Center; Richard A. Sater, MD, PhD, Guilford Neurological Associates; Marcus Rice, MD, Neurology Specialists; Ilya Kister, MD, NYU School of Medicine

Fingolimod and Cryptococcus: A Reminder of the Intersection between Immunomodulation and Infectious Disease
Rohini D Samudralwar, MD, Washington University in St. Louis; Ann Cross, MD, Washington University in St. Louis
PDF
6 Month Results from a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS), Demonstrates Complete Elimination of Gd-Enhancing Lesions
Matilde Inglese, MD, PhD, Mount Sinai School of Medicine; Maria Petracca, MD, PhD, Icahn School of Medicine at Mount Sinai; Sirio Cocozza, MD, Icahn School of Medicine at Mount Sinai; Sibyl Wray, MD, Hope Neurology MS Center; Michael K Racke, MD, Wexner Medical Center, Ohio State University; Richard Shubin, MD, SC3 Research Group, Inc; Cary L Twyman, MD, Associates in Neurology PSC, Lexington, KY, USA; Wendy Su, PhD, TG Therapeutics, Inc; James Eubanks, PhD, TG Therapeutics, Inc; Koby Mok, PhD, TG Therapeutics, Inc; Michael Weiss, JD, TG Therapeutics, Inc; Edward J. Fox, MD, PhD, Central Texas Neurology Consultants

Myelin Water Fraction As a Potential Marker of Progression in Primary Progressive Multiple Sclerosis
Kimberley Chang, ., University of British Columbia; Irene Vavasour, PhD, University of British Columbia; Roger Tam, ., University of British Columbia; David Clayton, ., Genentech, Inc.; Victoria Levesque, PhD, Genentech, Inc.; David Li, MD, FRCPC, University of British Columbia; Anthony Traboulsee, MD, University of British Columbia; Shannon Kolind, PhD, University of British Columbia
PDF
See more of: Poster